Why Wall Street is excited about a $39,800 pancreatic cancer pill
FDA-approved drug could usher in a groundbreaking era in cancer treatment.
1Breakthrough approval
The FDA approved Revolution Medicines' daily pill Rasonque, targeting RAS protein mutations responsible for 90% of pancreatic cancers. For metastatic pancreatic adenocarcinoma patients, the drug doubles survival time compared to previous treatments. Brian Wolpin from Dana-Farber Cancer Institute called this 'proof that RAS inhibition can make a striking difference for patients.'
2Impressive clinical results
In pre-approval trials, Rasonque showed a median survival of 13.2 months versus 6.7 months with standard chemotherapy. The drug reduced death risk by 60% while delaying disease progression. Anna Berkenblit of Pancreatic Cancer Action Network described these results as 'the most significant advance we've seen against pancreatic cancer.'
3FDA's accelerated process
The drug was evaluated under FDA's National Priority Voucher pilot program, receiving Orphan Drug and Breakthrough Therapy status. The review process, completed 6.5 months early, involved parallel assessments by international regulators. FDA's Oncology Center director Angelo de Claro highlighted 'unprecedented results in an area of high unmet need.'
4Pancreatic cancer's grim statistics
Per American Cancer Society's 2026 report, 67,530 new pancreatic cancer cases will be diagnosed in the US, with 52,740 deaths expected. With a five-year survival rate of just 13% (dropping to 3% for late-stage diagnoses), Revolution Medicines notes 80% of patients are diagnosed after metastasis occurs.
5$39,800 price tag
A 30-day supply of Rasonque carries a list price of $39,800, though insured patients may pay $0 through a support program. The expanded access program launched in May has already reached over 2,000 patients. This pricing has captured Wall Street investors' attention.
6Potential of RAS platform
Early investor Dr. Danish Nagda noted RAS mutations appear in a quarter of all human cancers, calling this 'not just a pancreatic cancer drug but a platform targeting the core RAS issue.' He predicts widespread off-label use for other cancers and potential revolution when combined with Moderna/Merck's mRNA vaccines.
7Molecular-level revolution
Nagda emphasized Rasonque is among the first treatments targeting cancer cells' internal mechanisms. Unlike mRNA vaccines attacking surface proteins, this drug halts intracellular molecular processes. 'We can now attack cells from both outside and inside,' he said, predicting this combination could transform cancer treatment within 5-10 years.
8Post-cancer era on horizon
Experts agree Rasonque's approval offers hope beyond pancreatic cancer to all RAS-mutated cancers. Nagda stated 'We're perhaps half a decade away from a post-cancer era.' The drug's success boosts investor interest in Revolution Medicines while potentially accelerating RAS inhibitor research across biotech.